MYR Pharmaceuticals

Dec 10, 2020

Gilead Sciences to Acquire MYR GmbH

Sep 17, 2020

MYR Pharmaceuticals launches HEPCLUDEX® in Germany, France and Austria

Aug 04, 2020

MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX®

Jun 10, 2020

MYR Pharmaceuticals has incorporated its first European subsidiary in France

May 29, 2020

MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections